Compare COHR & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COHR | ALNY |
|---|---|---|
| Founded | 1971 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.2B | 52.9B |
| IPO Year | 1995 | 2004 |
| Metric | COHR | ALNY |
|---|---|---|
| Price | $247.21 | $314.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 28 |
| Target Price | $214.25 | ★ $472.78 |
| AVG Volume (30 Days) | ★ 5.4M | 1.0M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 71.74 | ★ 206.88 |
| EPS | 1.95 | ★ 2.33 |
| Revenue | ★ $1,158,794,000.00 | $1,037,418,000.00 |
| Revenue This Year | $21.62 | $52.78 |
| Revenue Next Year | $23.75 | $31.86 |
| P/E Ratio | ★ $128.56 | $137.58 |
| Revenue Growth | 19.21 | ★ 22.88 |
| 52 Week Low | $45.58 | $205.87 |
| 52 Week High | $300.20 | $495.55 |
| Indicator | COHR | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 50.30 | 37.35 |
| Support Level | $170.95 | $309.57 |
| Resistance Level | $247.15 | $333.70 |
| Average True Range (ATR) | 19.59 | 9.15 |
| MACD | -3.21 | 0.76 |
| Stochastic Oscillator | 20.13 | 7.75 |
Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.